Cancer-related inflammation

@article{Mantovani2008CancerrelatedI,
  title={Cancer-related inflammation},
  author={Alberto Mantovani and Paola Allavena and Antonio Sica and Frances R Balkwill},
  journal={Nature},
  year={2008},
  volume={454},
  pages={436-444}
}
The mediators and cellular effectors of inflammation are important constituents of the local environment of tumours. In some types of cancer, inflammatory conditions are present before a malignant change occurs. Conversely, in other types of cancer, an oncogenic change induces an inflammatory microenvironment that promotes the development of tumours. Regardless of its origin, 'smouldering' inflammation in the tumour microenvironment has many tumour-promoting effects. It aids in the… Expand

Paper Mentions

Observational Patient Registry Clinical Trial
This study is a case controlled analytical study that analyzes the relationship between levels of inflammatory markers with the type of brain tumor. Samples of 35 people were then… Expand
ConditionsBrain Tumor
InterventionDiagnostic Test
Observational Clinical Trial
Sarcopenia is an important component of cachexia associated with cancer, and their high incidence in cancer patients emphasizes the need for a better understanding of its… Expand
ConditionsCachexia; Cancer; Sarcopenia
Molecular pathways and targets in cancer-related inflammation
Abstract Selected inflammatory conditions increase the risk of cancer. An inflammatory component is present also in the micro-environment of tumours epidemiologically unrelated to inflammation. AnExpand
Inflammation as target in cancer therapy.
TLDR
Encouraging results open new perspectives of combination treatments aimed at reducing cancer-promoting inflammation to maximize the anti-tumour efficacy. Expand
Chronic inflammation, the tumor microenvironment and carcinogenesis.
TLDR
The proposed mechanisms that lead to the recruitment of bone marrow derived cells are summarized, and the genetic and epigenetic alterations that may occur in inflammation associated cancers are explored. Expand
Chronic inflammation, the tumor microenvironment and carcinogenesis
TLDR
The proposed mechanisms that lead to the recruitment of bone marrow derived cells are summarized, and the genetic and epigenetic alterations that may occur in inflammation associated cancers are explored. Expand
Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability.
TLDR
This work surmises that CRI represents the seventh hallmark of cancer, and suggests that an additional mechanism involved in cancer-related inflammation (CRI) is induction of genetic instability by inflammatory mediators, leading to accumulation of random genetic alterations in cancer cells. Expand
Molecular Determinants of Cancer-Related Inflammation
Tumor cells communicate with the cells of their microenvironment via a series of molecular and cellular interactions to aid their progression to a malignant state and ultimately their metastaticExpand
Inflammation in the context of oral cancer.
TLDR
The purpose of this article is to elaborate on some of the more important relationships between oral cancer and inflammation, and to comment on the role of inflammation in the pathogenesis of oral squamous cell carcinoma. Expand
Cancer Inflammation and Cytokines.
TLDR
Tumor-associated macrophages and TANs are both integrated in cancer-related inflammation and an ever better understanding of their functions can be useful to tailor the use of anticancer therapeutic approaches and patient follow-up. Expand
Cellular and molecular pathways linking inflammation and cancer.
TLDR
Although the connection between inflammation and cancer is unequivocal the mechanistic basis of such association are largely unknown, recent advances in the understanding of the cellular and molecular pathways involved in cancer-related inflammation as well as their potential relevance as diagnostic, prognostic and therapeutic targets are discussed. Expand
The Pro-inflammatory Milieu and Its Role in Malignant Epithelial Initiation
TLDR
Examples of how inflammation may lead to cancer formation include enhanced proliferation of initiated cells, through resistance to apoptosis, induction of genomic instability, alterations in epigenetic events and subsequent inappropriate gene expression, abnormal tumor neovascularization or angiogenesis, and the promotion of metastasis among others. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 110 REFERENCES
IL-23 promotes tumour incidence and growth
TLDR
It is shown that IL-23 is an important molecular link between tumour-promoting pro-inflammatory processes and the failure of the adaptive immune surveillance to infiltrate tumours. Expand
Inflammation and cancer: back to Virchow?
TLDR
A rationale for the use of cytokine and chemokine blockade, and further investigation of non-steroidal anti-inflammatory drugs, in the chemoprevention and treatment of malignant diseases is provided. Expand
Tumour immunology: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment
TLDR
Signal transducer and activator of transcription 3 (STAT3) propagates several levels of crosstalk between tumour cells and their immunological microenvironment, leading to tumour-induced immunosuppression and has emerged as a promising target for cancer immunotherapy. Expand
Altered macrophage differentiation and immune dysfunction in tumor development.
TLDR
A complete understanding of the complex interplay between neoplastic and myelomonocytic cells might offer novel targets for therapeutic intervention aimed at depriving tumor cells of important growth support and enhancing the antitumor immune response. Expand
Smoldering and polarized inflammation in the initiation and promotion of malignant disease.
TLDR
A number of clinical trials of TNF-α antagonists alone, and in combination with other therapies, are currently underway in cancer patients, and there are suggestions of activity against advanced disease in advanced ovarian and renal cell cancer. Expand
Inflammation, inflammatory cells and angiogenesis: decisions and indecisions
TLDR
The immune system itself represents a major pharmaceutical target and links angiogenesis inhibition to immunotherapy, and it is found that neutrophils, myeloid-derived suppressor and dendritic cells clearly have the potential for influencing tumorAngiogenesis. Expand
NF-κB functions as a tumour promoter in inflammation-associated cancer
TLDR
It is shown that the inflammatory process triggers hepatocyte NF-κB through upregulation of tumour-necrosis factor-α (TNFα) in adjacent endothelial and inflammatory cells, and is therefore a potential target for cancer prevention in chronic inflammatory diseases. Expand
Tumour necrosis factor α: a potential target for the therapy of solid tumours
TLDR
There is convincing evidence that under specific conditions TNFalpha is a tumour promoter and helps to produce the toxic effects associated with conventional cancer therapy, such as the cytokine release syndrome and cisplatin-induced nephrotoxicity. Expand
De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent.
TLDR
It is reported that genetic elimination of mature T and B lymphocytes in a transgenic mouse model of inflammation-associated de novo epithelial carcinogenesis, e.g., K14-HPV16 mice, limits neoplastic progression to development of epithelial hyperplasias that fail to recruit innate immune cells. Expand
Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis.
TLDR
Using a tumor xenograft model, it is shown that Ras-dependent CXCL-8 secretion is required for the initiation of tumor-associated inflammation and neovascularization and a novel mechanism by which the Ras oncogene can elicit a stromal response that fosters cancer progression. Expand
...
1
2
3
4
5
...